Brief Report from the 3rd International Symposium

Molecular Pathogenesis and Therapy of HSAN1 was held November 14-16, 2013 in Boston. During the course of the 3-day meeting, about a dozen researchers from around the world presented their work on various aspects of HSAN1, including updates on current research in mice and humans, structural biology and subunits of the SPT enzyme, deoxysphingoid bases, as well as new insights into programmed axonal cell death. Other neuropathies relative to HSAN1 were discussed, and lessons learned from previous clinical trials in peripheral neuropathies were also presented.

The meeting concluded with a discussion on potential therapies for HSAN1 and possible new research avenues to explore moving forward. There was also a unanimous interest in holding more HSAN1 conferences in the future and also seeing if research pertaining to HSAN1 could be integrated into the broader-scale neuropathy symposiums held throughout the year, like the annual International Charcot-Marie-Tooth Consortium and/or Peripheral Neuropathy Meetings.

All in all, this 3rd symposium was a productive time of research presentation, idea discussion, and potential therapy proposals by these top researchers in order to further the goal of developing a treatment and cure for patients with HSAN1.